Global Gastrointestinal Partnering Deal Trends, Players and Financials Directory 2014-2019


DUBLIN, March 11, 2019 — The “Global Gastrointestinal Partnering 2014-2019: Deal Trends, Players and Financials” report has been added to’s offering.

Global Gastrointestinal Partnering 2014 to 2019 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Gastrointestinal dealmaking

2.1. Introduction

2.2. Gastrointestinal partnering over the years

2.3. Gastrointestinal partnering by deal type

2.4. Gastrointestinal partnering by industry sector

2.5. Gastrointestinal partnering by stage of development

2.6. Gastrointestinal partnering by technology type

2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering

3.1. Introduction

3.2. Disclosed financials terms for Gastrointestinal partnering

3.3. Gastrointestinal partnering headline values

3.4. Gastrointestinal deal upfront payments

3.5. Gastrointestinal deal milestone payments

3.6. Gastrointestinal royalty rates

Chapter 4 – Leading Gastrointestinal deals and dealmakers

4.1. Introduction

4.2. Most active in Gastrointestinal partnering

4.3. List of most active dealmakers in Gastrointestinal

4.4. Top Gastrointestinal deals by value

Chapter 5 – Gastrointestinal contract document directory

5.1. Introduction

5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 – Gastrointestinal dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Gastrointestinal therapeutic target


Appendix 1 – Directory of Gastrointestinal deals by company A-Z 2014 to 2019

Appendix 2 – Directory of Gastrointestinal deals by deal type 2014 to 2019

Appendix 3 – Directory of Gastrointestinal deals by stage of development 2014 to 2019

Appendix 4 – Directory of Gastrointestinal deals by technology type 2014 to 2019

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

Mazda CX-9 2022: precios y empaque

IRVINE, California, 8 de diciembre de 2021 /PRNewswire-HISPANIC PR WIRE/ — Como el SUV crossover mediano de tres filas insignia de Mazda, el CX-9 ha sido fundamental

Wilson Sonsini wählt 23 neue Partner

– Neue Partner von Wilson Sonsini: eine nicht-binäre Person, acht Frauen und 14 Männer aus den Bereichen Unternehmensrecht, Rechtsstreitigkeiten, geistiges Eigentum, Aufsichtsrecht und Technologietransaktionen der Kanzlei

Wilson Sonsini élit 23 nouveaux associés

– Parmi les associés cooptés par Wilson Sonsini figurent une personne non binaire, huit femmes et 14 hommes issus des diverses pratiques du cabinet, notamment celles de l’entreprise,